Other

Roche to pay $7.1 bn for Telavant Holdings

Swiss pharmaceutical group Roche said Monday it will pay $7.1 billion to buy Telavant Holdings, a group developing new treatments for inflammatory bowel diseases.

Medical research

Deep dive into the gut unlocks new disease treatments

The more diverse species in your gut, the better it is for your health. Now an international team led by the Hudson Institute of Medical Research has found a way to determine which species are important and how they interact ...

Oncology & Cancer

Study shows promise for iNKT cell platform to treat cancer

Allogeneic invariant natural killer T cells (allo-iNKTs) from a healthy donor have been shown to have therapeutic effects in treatment-resistant cancers and improve survival from COVID-19-related acute respiratory failure ...

page 11 from 40